Conmind Medical completes nearly RMB 200 million Series C financing, leading rapid development of Brain-Computer Interface technology

Recently, Conmind Medical, a company committed to becoming a globally leading brain medical technology platform, completed nearly RMB 200 million in Series C financing. This round was led by the Zhongshan Biopharmaceutical Angel Fund under Zhongshan Investment Holdings, with participation from the biopharmaceutical fund under Yuecai Zhongyin Private Equity, Guangdong Technology Financial Group, King Tower Capital Group, and Jinhang Qiying Fund. Existing shareholder Zhuhai Hi-Tech Financial Investment continued to add investment. X&Q Capital served as the exclusive financial advisor for this round.

The successful closing of this financing marks significant recognition from the capital market for Conmind Medical's dual-driven strategy of "brain-computer interface and heart-repairing and brain-protecting," injecting strong capital momentum for the company's next phase of rapid development.

Through minimally invasive interventional technologies and a brain-computer interface platform, Conmind Medical has built a full-cycle solution for brain medical diseases covering prevention, treatment, and functional reconstruction. The core team possesses extremely strong resource integration capabilities and proven commercial success experience in the brain medical field. In its early stages, Conmind Medical developed a comprehensive product matrix for interventional treatment of cerebrovascular diseases, overcoming key research, development, and manufacturing processes in materials, precision processing, and delivery systems, while simultaneously completing the layout of core components and underlying technologies for brain-computer interfaces.

Leveraging deep insights into brain medical diseases and clinical pain points, Conmind Medical has developed a breakthrough, globally innovative heart-repairing and brain-protecting device solution, with related products having successfully completed all clinical trials. In the near future, Conmind Medical will combine its innovative brain-computer interface technology with solid device research, development, and manufacturing capabilities, starting with closed-loop neuromodulation therapies such as interventional brain-computer interfaces, to build an open and innovative brain medical technology platform.